Holen Sie sich die Stockscreener-App
8.91
9.19%
0.75
Schlusskurs vom Vortag:
$8.16
Offen:
$8.24
24-Stunden-Volumen:
1.94M
Relative Volume:
1.42
Marktkapitalisierung:
$475.36M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.6037
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+46.07%
1M Leistung:
+21.06%
6M Leistung:
-5.91%
1J Leistung:
+33.58%
1-Tages-Spanne:
$8.24
$9.13
1-Wochen-Bereich:
$6.03
$9.28
52-Wochen-Spanne:
$4.02
$13.28
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.91 | 435.34M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
149.77 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.63 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.58 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.60 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.39 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions’ Strong Q2 Fuels Hopes for 2025 Rally - citybiz
300 new jobs headed to Bayview manufacturing plant - The Business Journals
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
Emergent BioSolutions Reports Improved Q2 2025 Results - TipRanks
Published on: 2025-08-10 18:27:00 - metal.it
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50 - simplywall.st
Emergent BioSolutions Inc. (NYSE:EBS) Q2 2025 Earnings Call Transcript - Insider Monkey
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - MSN
Emergent BioSolutions' Strong ROE Amid Industry Average: A Financial Analysis - AInvest
Can Emergent BioSolutions Inc. (NYSE:EBS) Maintain Its Strong Returns? - Yahoo Finance
Emergent BioSolutions to participate in investor conferences in May and June 2025. - AInvest
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Exceeds Q2 Revenue Guidance, Raises Full-Year Profitability Guidance - AInvest
BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd - Law360
Emergent BioSolutions Surpasses Q2 Revenue Expectations - The Globe and Mail
Emergent BioSolutions reports Q2 adjusted EPS 16c vs ($2.32) last year - TipRanks
Emergent BioSolutions Soars 22% on Earnings Surprise: What's Fueling the Surge? - AInvest
Emergent Biosolutions reports second quarter loss - Maryland Daily Record
Emergent Biosolutions shares rise 6.14% premarket after securing $51.9 million contract modification for smallpox preparedness. - AInvest
Installed Building Products reports record Q2 2025 results, 3.1% revenue increase. - AInvest
Emergent Biosolutions Q2 Earnings Report: $12 Million LossNews and Statistics - IndexBox
Emergent Biosolutions: Q2 Earnings Snapshot - Huron Daily Tribune
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Emergent BioSolutions Q2 2025 results show mixed performance - Investing.com
Emergent BioSolutions Outpaces Its Own Forecasts But Misses Analyst Targets - Finimize
Emergent Biosolutions earnings beat by $0.26, revenue fell short of estimates - Investing.com Canada
Emergent BioSolutions Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Emergent BioSolutions Q2 revenue misses analyst expectations - MarketScreener
Emergent BioSolutions Q2 2025 slides: Profitability improves as transformation continues - Investing.com Canada
Emergent Biosolutions Q2 Earnings: Non-GAAP EPS Beats by $0.65, Revenue Misses by $5.47M - AInvest
Emergent BioSolutions Reports Second Quarter 2025 Financial Results - The Manila Times
Emergent BioSolutions Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
What drives Emergent BioSolutions Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
Is it the right time to buy Emergent BioSolutions Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
How many analysts rate Emergent BioSolutions Inc. as a “Buy”Strong return on assets - Jammu Links News
What catalysts could drive Emergent BioSolutions Inc. stock higher in 2025Access high-yield investment alerts now - Jammu Links News
Is Emergent BioSolutions Inc. stock overvalued or undervaluedTriple returns potential - Jammu Links News
Why is Emergent BioSolutions Inc. stock attracting strong analyst attentionInvest smarter and grow your wealth faster - Jammu Links News
What are the technical indicators suggesting about Emergent BioSolutions Inc.Stock Market Ideas With Proven Results - Jammu Links News
Insider Sellers Might Regret Selling Emergent BioSolutions Shares at a Lower Price Than Current Market Value - simplywall.st
What institutional investors are buying Emergent BioSolutions Inc. stockPost Market Outlook For Every Investor - Jammu Links News
Why Emergent BioSolutions Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - beatles.ru
Can Emergent BioSolutions Inc. recover in the next quarterReal-Time Analysis With Entry Targets In Progress - metal.it
Emergent BioSolutions Inc. Recovery Hinges on Volume BreakoutPotential Breakout Stock List Published This Week - metal.it
Investors Hope for Bounce in Emergent BioSolutions Inc. After SelloffAI Based High Gain Watchlist Scanner Shared - metal.it
Can Emergent BioSolutions Inc. Regain Momentum After BreakdownCapital Growth With Controlled Risk Picks Suggested - metal.it
Published on: 2025-07-29 03:10:46 - metal.it
Emergent BioSolutions (EBS) Applauds Naloxone Accessibility in U - GuruFocus
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - The Manila Times
Emergent BioSolutions Commends U.S. House of Representatives for Naloxone Accessibility Initiative - Quiver Quantitative
U.S. House Takes Historic Step: NARCAN Now Available in Every Building to Prevent Opioid Deaths - Stock Titan
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):